Director of Cell Therapy, Technical Development Sangamo Therapeutics, Inc
CAR-Tregs are an emerging therapeutic approach to treat autoimmune diseases. Due to the low quantity of circulating Tregs, there are unique process development challenges not experienced with traditional CAR T approaches. This presentation will cover a brief background for Tregs, basic unit operations, and challenges associated with process development.
Learning Objectives:
understand the limitations of experimental design due to scale of Tregs
discuss the challenges of integrating the different unit operations in automated platforms
